The Hydropothecary Corporation is a buy, says Echelon Wealth

Gatineau, Quebec’s The Hydropothecary Corporation (TSXV:THCX) gets a 12-month target price increase from Echelon Wealth Partners’ Russell Stanley, who sees the licensed cannabis producer to be trading at a discount to its peer group of cannabis companies.

On Thursday, the analyst’s research update reiterated his “Speculative Buy” rating with a new target of $6.75 (up from $5.50).

Attending the Hydropothecary Corp.’s Investor Day in New York City on Wednesday, Stanley says the key takeaway was that the company expects dried cannabis to eventually be commoditized, and thus that the real money will be in consumer packaged goods.

The analyst agrees with this premise.

“Management’s overall goal is to become a consumer packaged goods (CPG) company with 35-40 per cent EBITDA margins, with straight cultivation operating margins likely trending to the mid-single digit range over time as supply increases,” he says.

“Geographically, management views its penetration of the Québec market as the beachhead for its expansion into other provinces, predominantly to the west. Once the Company’s position in Canada has been strengthened, and adult-use is legalized in other markets, international expansion becomes a bigger priority,” says Stanley.

Stanley asserts that THCX is second only to Canopy Growth Corp in terms of aggregate sales commitments but that relative to its capacity plans (108,000 kg of dried cannabis annually), the Hydropothecary has pre-sold more of its production than any other licensed producer.

The analyst says that potential catalysts going forward include supply contract developments, expansion progress updates, product development news, a TSX graduation and improved financial results. The analyst also notes that THCX’s fully-funded capacity expansion plans and sales visibility make it an attractive M&A candidate.

The $6.75 target price comes from a 19x C2019 EBITDA estimate valuation multiple and represents a projected return of 33 per cent at the time of publication.

We Hate Paywalls Too!

At Cantech Letter we prize independent journalism like you do. And we don't care for paywalls and popups and all that noise That's why we need your support. If you value getting your daily information from the experts, won't you help us? No donation is too small.

Make a one-time or recurring donation

Tagged with: thcx
Nick Waddell

Cantech Letter founder and editor Nick Waddell has lived in five Canadian provinces and is proud of his country's often overlooked contributions to the world of science and technology. Waddell takes a regular shift on the Canadian media circuit, making appearances on CTV, CBC and BNN, and contributing to publications such as Canadian Business and Business Insider.

Recent Posts

It’s time to buy cannabis stocks, this analyst says

A major development came down the pipe this week at the U.S. Drug Enforcement Agency has reportedly decided to reschedule… [Read More]

13 hours ago

Is Generac stock a buy?

Following the company's first quarter results, Roth MKM analyst Chip Moore remains neutral on Generac Holdings (Generac Holdings Stock Quote,… [Read More]

23 hours ago

Bombardier is a buy, Desjardins says (May, 2024)

The stock has climbed slowly but surely since last October. But is there still money to be made on Bombardier?… [Read More]

1 day ago

Should you buy AMZN? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Rohit Kulkarni has maintained his "Buy" rating on Amazon (Amazon Stock… [Read More]

2 days ago

These cannabis stocks will benefit most from reclassification

It happened. The move that everyone in the cannabis sector was hoping for came about swiftly on the last day… [Read More]

2 days ago

Is AMD stock a buy? (May, 2024)

Following the company's first quarter results, Roth MKM analyst Suji Desilva has maintained his "Buy" rating on Advanced Micro Devices… [Read More]

2 days ago